Bio

Xuelin Wang has extensive experience representing issuers and underwriters in international capital markets transactions, including initial public offerings and follow-on equity offerings, investment-grade and high-yield debt offerings, and liability management transactions. He also advises clients ranging from early-stage privately held companies to public companies on corporate governance, securities law compliance, strategic transactions and other corporate law matters. Steve has a Ph.D. in cell biology. He advises biotech and healthcare companies on their most important transactions. His practice also spans a variety of other industries, including technology, consumer and retail, and real estate. Steve was recognized as a “Rising Star” at the 2021 China Law & Practice Awards and the 2020 IFLR Asia-Pacific Awards.